BMC Neuroscience issued an editorial expression of concern over a 2012 study claiming the diabetes drugs liraglutide and lixisenatide cross the blood–brain barrier and enhance neurogenesis. The journal says concerns center on possible image overlap—specifically a micrograph in Figure 2 appearing to overlap with a previously published image cited as Figure 4K. The journal cautioned that results should be interpreted with caution while the issue remains unresolved. The expression of concern was published on Oct. 29, 2026 by Kerry Hunter and Christian Hölscher, and the publisher noted it could not contact Hunter; Hölscher’s agreement or disagreement with the notice is not clearly stated. For researchers using mechanistic claims as downstream rationale, the notice is a direct reminder that image-level integrity can change how preclinical neuroscience hypotheses are treated. —